Sascha Behne

Mr. Sascha Behne

Berliner Hochschule für Technik, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Sascha BehneSascha Behne
Sascha Behne
HFHeike Franke
Heike Franke
Steffen SchwarzSteffen Schwarz
Steffen Schwarz
Dirk W. LachenmeierDirk W. Lachenmeier
Dirk W. Lachenmeier
Chlorogenic and isochlorogenic acids are naturally occurring antioxidant dietary polyphenolic compounds found in high concentrations in plants, fruits, vegetables, coffee, and coffee by-products. The objective of this review was to assess the potential health risks associated with the oral consumption of coffee by-products containing chlorogenic and isochlorogenic acids, considering both acute and chronic exposure. An electronic literature search was conducted, revealing that 5-caffeoylquinic acid (5-CQA) and 3,5-dicaffeoylquinic acid (3,5-DCQA) are the major chlorogenic acids found in coffee by-products. Toxicological, pharmacokinetic, and clinical data from animal and human studies were available for the assessment, which indicated no significant evidence of toxic or adverse effects following acute oral exposure. The current state of knowledge suggests that long-term exposure to chlorogenic and isochlorogenic acids by daily consumption does not appear to pose a risk to human health when observed at doses within the normal range of dietary exposure. As a result, the intake of CQAs from coffee by-products can be considered reasonably safe.

16 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Sascha BehneSascha Behne
Sascha Behne
Dirk W. LachenmeierDirk W. Lachenmeier
Dirk W. Lachenmeier
Background: The acyclic monoterpene β-myrcene (CAS No. 123-35-3) is a food flavoring classified by the International Agency for Research on Cancer (IARC) as “possibly carcinogenic to humans” (Group 2B) based on neoplastic findings in rodents. Its toxicological relevance is closely tied to its metabolic fate: CYP-mediated epoxidation yields reactive intermediates that are rapidly detoxified to diols, and the weight of evidence supports a non-genotoxic, threshold mode of action. This study therefore combined this metabolic understanding with benchmark dose-response (BMD) modeling to derive a health-based guidance value (HBGV). Methods: Tumor-incidence data from the two-year National Toxicology Program (NTP) gavage studies in rats and mice were modeled with BMDS Online version 25.1 from US EPA, following international guidelines. A benchmark response (BMR) of 10% extra risk and a 95% lower confidence limit were applied. Models were evaluated by goodness of fit and Akaike information criterion (AIC). Results: The BMDL₁₀ of 25.4 mg/kg b.w./day for hepatocellular adenoma (including multiple) in male mice was selected as the point of departure (POD). Applying an uncertainty factor of 100 yielded an acceptable daily intake (ADI) of 0.25 mg/kg b.w./day, equivalent to 250 µg/kg b.w./day. At estimated flavoring intakes of 3–138 µg/kg b.w./day, the ADI-to-intake ratio ranged from approximately 83 to 1.8. Conclusion: Thus, an ADI of 0.25 mg/kg b.w./day can be proposed for β-myrcene. Estimated flavoring intakes remain below this value; however, the margin at the upper exposure estimate is limited to approximately 1.8.

30 October 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
Sascha BehneSascha Behne
Sascha Behne
Dirk W. LachenmeierDirk W. Lachenmeier
Dirk W. Lachenmeier
Background: The acyclic monoterpene β-myrcene (CAS No. 123-35-3) is a food flavoring classified by the International Agency for Research on Cancer (IARC) as “possibly carcinogenic to humans” (Group 2B) based on neoplastic findings in rodents. Its toxicological relevance is closely tied to its metabolic fate: CYP-mediated epoxidation yields reactive intermediates that are rapidly detoxified to diols, and the weight of evidence provides no indication of DNA reactivity. Separately, a threshold-based dose–response approach was adopted as a pragmatic default assumption, consistent with EFSA and JECFA practice, rather than as an inferred mode of action. This study therefore combined this metabolic understanding with benchmark dose–response (BMD) modeling to derive a health-based guidance value (HBGV). Methods: Tumor-incidence data from the two-year National Toxicology Program (NTP) gavage studies in rats and mice were modeled with BMDS Online version 25.1 from US EPA, following international guidelines. Doses administered on five days per week were converted to time-weighted average daily doses before modeling. The 1000 mg/kg dose group was excluded from modeling because survival at that dose indicated that the maximum tolerated dose had been exceeded. A benchmark response (BMR) of 10% extra risk and a 95% lower confidence limit were applied. Models were evaluated by goodness of fit and Akaike information criterion (AIC). Results: The BMDL10 of 18.2 mg/kg b.w./day for hepatocellular adenoma (including multiple) in male mice was selected as the point of departure (POD). Applying an uncertainty factor of 100 yielded an acceptable daily intake (ADI) of 0.18 mg/kg b.w./day, equivalent to 180 µg/kg b.w./day. At estimated flavoring intakes of 3–138 µg/kg b.w./day, the ratio of the ADI to the estimated intake, which is not a margin of exposure in the EFSA sense, ranged from approximately 60 to 1.3. This comparison covers flavoring use alone and does not include other dietary or non-dietary sources of β-myrcene. Conclusions: Thus, an ADI of 0.18 mg/kg b.w./day can be proposed for β-myrcene. Estimated flavoring intakes remain below this value; however, the threshold assumption introduces additional uncertainty, and the margin at the upper exposure estimate is limited to approximately 1.3.